Profiles Leading Market Competitors, Including FUJIFILM CDI, ReproCELL, Evotec, Ncardia, and Axol Bioscience
Since the discovery of induced pluripotent stem cell (iPSC) technology 15 years ago, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated.
iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and potentially, treat previously incurable diseases. The somatic cells used for reprogramming include skin cells and blood cells, and to a lesser degree, other cell types such hair follicles, cord blood and urine.
iPS Cell Commercialization
Today, methods of commercializing iPSCs include:
- Cell Therapy: iPSCs are being explored in a diverse range of cell therapy applications for the purpose of reversing injury or disease.
- Disease Modelling: By generating iPSCs from patients with disorders of interest and differentiating them into disease-specific cells, iPSCs can effectively create disease models “in a dish.”
- Drug Development and Discovery: iPSCs have the potential to transform drug discovery by providing physiologically relevant cells for compound identification, target validation, compound screening, and tool discovery.
- Personalized Medicine: The use of techniques such as CRISPR enable precise, directed creation of knock-outs and knock-ins (including single base changes) in many cell types. Pairing iPSCs with genome editing technologies is adding a new dimension to personalized medicine.
- Toxicology Testing: iPSCs can be used for toxicology screening, which is the use of stem cells or their derivatives (tissue-specific cells) to assess the safety of compounds or drugs within living cells.
Other applications of iPSCs include their use as research products, as well as their integration into 3D bioprinting, tissue engineering, and clean meat production. Technology allowing for the mass-production and differentiation of iPSCs in industrial-scale bioreactors is also advancing at breakneck speed.
The Era of iPSCs
In recent years, iPSC-derived cells have increasingly been used to within preclinical testing and early stage-stage clinical trials. The first clinical trial using iPSCs started in 2008, and today, that number has surpassed 100 worldwide. Most of the current clinical trials do not involve the transplant of iPSCs into humans, but rather, the creation and evaluation of iPSC lines for clinical purposes. Within these trials, iPSC lines are created from specific patient populations to determine if these cell lines could be a good model for a disease of interest.
The therapeutic applications of induced pluripotent stem cells (iPSCs) have also surged in recent years. Since the discovery of iPSCs in 2006, it took only seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2013. From 2013 to present, several clinical trials and physician-led studies employing human iPSC-derived cell types have been initiated.
2013 was a landmark year because it saw the first cellular therapy involving the transplant of iPSCs into humans initiated at the RIKEN Center in Kobe, Japan. Led by Dr. Masayo Takahashi, it investigated the safety of iPSC-derived cell sheets in patients with macular degeneration.
In another world first, Cynata Therapeutics received approval in 2016 to launch the first formal clinical trial of an allogeneic iPSC-derived cell product (CYP-001) for the treatment of GvHD. CYP-001 is a iPSC-derived MSC product. In this historic trial, CYP-001 met its clinical endpoints and produced positive safety and efficacy data for the treatment of steroid-resistant acute GvHD.
Given this early success, Cynata is advancing its iPSC-derived MSCs into Phase 2 trials for the severe complications associated with COVID-19, as well as GvHD and critical limb ischemia (CLI). It is also undertaking an impressive Phase 3 trial that will utilize Cynata’s iPSC-derived MSC product, CYP-004, in 440 patients with osteoarthritis (OA). This trial represents the world’s first Phase 3 clinical trial involving an iPSC-derived cell therapeutic product and the largest one ever completed.
Not surprisingly, the Japanese behemoth FUJIFILM has been involved with the co-development and commercialization of Cynata’s iPSC-derived MSCs through its 9% ownership stake in the company. Headquartered in Tokyo, Fujifilm is one of the largest players in regenerative medicine field. It has pursued a broad base in regenerative medicine across multiple therapeutic areas through its acquisition of Cellular Dynamics International (CDI) and Japan Tissue Engineering Co. Ltd. (J-Tec). The Japanese company Healios K.K. is also preparing, in collaboration with Sumitomo Dainippon Pharma, for a clinical trial using allogeneic iPSC-derived retinal cells to treat age-related macular degeneration (AMD).
Riding the momentum within the CAR-T field, Fate Therapeutics is developing FT819, its off-the-shelf iPSC-derived CAR-T cell product candidate. FT819 is the world’s first CAR T therapy derived from a clonal master iPSC line and is engineered with several novel features designed to improve the safety and efficacy of CAR T-cell therapy. Notably, the use of a clonal master iPSC line as the starting cell source could enable CAR-T cells to be mass produced and delivered off-the-shelf at an industrial scale.
Other companies and organizations with iPSC-derived cell therapeutics under development worldwide include:
- Allele Biotechnology & Pharmaceuticals is developing a diabetes drug created from iPSC-derived pancreatic beta cells.
- Aspen Neuroscience is combining stem cell biology and genomics to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson disease.
- Avery Therapeutics and I Peace, Inc., are collaborating to advance an iPSC-derived cell therapeutic for heart failure. I Peace is generating and supplying GMP-grade iPSCs, while Avery Therapeutics is using them to manufacture its MyCardia™ product.
- Bayer acquired iPSC cell therapy company BlueRock Therapeutics in August 2019. Since May 2021, BlueRock Therapeutics, Fujifilm Cellular Dynamics, and Opsis Therapeutics have had an R&D alliance to develop allogeneic iPSC-derived cell therapies for ocular diseases.
- BlueRock Therapeutics, a subsidiary of Bayer since August 2019, develops iPSC-derived cell therapies to target Parkinson’s disease, heart failure, and ocular diseases.
- Bone Therapeutics has partnered with the U.S. company Implant Therapeutics to develop allogeneic, iPSC-derived MSCs.
- Brooklyn Immuno Therapeutics is developing a set of mesenchymal stem cell (MSC) products, derived from iPSCs, to which it also intends to apply its gene editing technology.
- Century Therapeutics was created in July 2019 by Versant Ventures and Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies.
- Citius Pharmaceuticals uses iPSCs from a single-donor dermal fibroblast to create iPSC-derived MSCs (i-MSCs). It has completed the development of an i-MSC Accession Cell Bank (ACB) and is testing and expanding these cells to create an allogeneic cGMP i-MSC Master Cell Bank.
- Cynata Therapeutics manufacturers iPSC-derived MSCs using its proprietary Cymerus™ technology. In partnership with FUJIFILM Corporation, it is clinically testing these cells for the treatment of graft-versus-host disease (GvHD). It is also conducting trials for the treatment of critical limb ischemia (CLI), osteoarthritis (OA), and respiratory failure/distress, including ARDS.
- Cytovia Therapeutics is developing allogeneic “off-the-shelf” gene-edited iNK and CAR (Chimeric Antigen Receptor)-iNK cells derived from iPSCs.
- Edigene, Inc. - Edigene and Neukio Biotherapeutics are developing allogenic iPSC-derived NK cell therapies through an R&D collaboration.
- Editas Medicine (Nasdaq: EDIT), a genome editing company, is developing engineered iPSC-derived natural killer cells (iNKs) for the treatment of cancer.
- Exacis Biotherapeutics is a development-stage immuno-oncology company that is developing NK cells from iPSCs (ExaNK™ cells) engineered using mRNA gene-editing technology to resist rejection by the patient’s immune system.
- Fate Therapeutics is developing iPSC-derived NK and CAR-T cells for the treatment of cancer and immune disorders.
- FUJIFILM Cellular Dynamics, Inc. (FCDI) is investing in a $21M cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products.
- Heartseed Inc. is a Japanese biotech company that is developing iPSC-derived cardiomyocytes (HS-001) for the treatment of heart failure. The company is positioned to initiate a phase 1/2 study of this investigational cell therapy in Japan in the second half of 2021.
- Healios K.K., in collaboration with Sumitomo Dainippon Pharma, is undertaking a clinical trial using allogeneic iPSC-derived retinal cells to treat age-related macular degeneration.
- Hopstem Biotechnology is one of the first iPSC cell therapy companies in China and a market leader in iPSC-derived clinical-grade cell products. In June 2021, it partnered with Neurophth Biotechnology to co-develop an iPSC-derived cell therapy for the treatment of ocular diseases. Hopstem has a proprietary neural differentiation platform, as well as a patented iPSC reprogramming method and GMP manufactory and quality systems.
- Implant Therapeutics is engineering iPSC-MSC cells containing FailSafe™ and induced Allogeneic Cell Tolerance (iACT Stealth Cell™) technologies. These iPSC MSC cells are hypo-immunogenic and can be used as ex-vivo gene therapy vehicles.
- I Peace, Inc. and Avery Therapeutics are collaborating to advance an iPSC-derived cell therapeutic for heart failure. I Peace is generating GMP-grade iPSCs, while Avery Therapeutics is using them to manufacture its MyCardia™ product. I Peace is able to mass production clinical-grade iPSC lines simultaneously in a single room using a miniaturized plate and robotic technology, and its facility is equipped with a fully-closed automated iPSC manufacturing system that meets the safety standards of the U.S. FDA and Japanese PMDA.
- Keio University won approval from the the Japanese government in February 2018 for an iPSC trial that involves the treatment of patients with spinal cord injuries (led by Professor Hideyuki Okano).
- Kyoto University Hospital, in partnership with the Center for iPS Cell Research and Application (CiRA), is performing a physician-led study of iPSC-derived dopaminergic progenitors in patients with Parkinson’s disease.
- Neurophth Biotechnology Ltd. is a gene therapy company specializing in AAV-mediated gene therapies for the treatment of ocular diseases. In June 2021, it partnered with Hopstem Biotechnology to develop an iPSC-derived candidate cell product for an agreed upon retinal degenerative disorder.
- Novo Nordisk signed a co-development agreement with Heartseed in mid-2021 that grants it exclusive rights to develop, manufacture, and commercialize HS-001 globally, excluding Japan where Heartseed retained exclusive rights to develop HS-001. HS-001 is an investigational therapy comprised of purified iPSC-derived ventricular cardiomyocytes for the treatment of heart failure.
- Osaka University grafted a sheet of iPS-derived corneal cells into the cornea of a patient with limbal stem cell deficiency, a condition in which corneal stem cells are lost.
- REPROCELL recently launched a “Personal iPS service” in Japan to prepare and store an individual’s iPSCs for the treatment of future illness or injury. Individual’s iPSCs are created from mature cells in their urine or dental pulp, using RNA reprogramming technology. The iPSCs are then stored at two locations in Japan and the U.S.
- RIKEN administered the world’s first iPSC-derived cell therapeutic into a human patient in 2014 when it transplanted an autologous iPSC-RPE cell sheet into a patient with AMD.
- RheinCell Therapeutics GmbH is a developer and manufacturer of GMP-compliant human iPSCs derived from HLA-homozygous, allogeneic umbilical cord blood. In January 2021, the company received GMP certification and Manufacturing Authorization within the EU.
- SCG Cell Therapy Pte Ltd (“SCG”) has acquired the rights to human iPSC technology, from the Agency for Science, Technology and Research (“A*STAR”)’s Accelerate Technologies Pte Ltd (“A*ccelerate”). SCG is using this iPSC technology to to expand its cell therapy product portfolio and develop off-the-shelf NK cell therapies.
- SCM Lifescience, a South Korean stem cell therapy developer, licensed exclusive rights within Korea for the development, approval, production, and sale of a diabetic cell therapy being developed by Allele Biotechnology and Pharmaceuticals. The $750K deal was signed in July 2021.
- Semma Therapeutics, which was acquired by Vertex Pharmaceuticals for $950 million in late 2019, is developing a treatment for Type 1 diabetes. This treatment consists of cells derived from iPSCs that behave like pancreatic cells.
- Shoreline Biosciences is a biotech company that is developing allogeneic “off-the-shelf” natural killer (NK) and macrophage cellular immunotherapies derived from iPSCs for cancer and other serious diseases.
- Stemson Therapeutics has been developing a therapy for hair loss involving generation of de novo hair follicles.
- TreeFrog Therapeutics has a 13,000 sq ft facility in France for the development and scale-up of its cell therapy manufacturing process that leverages human iPSCs. It plans to develop its own iPSC-derived therapies and support co-development programs.
- The U.S. NIH is undertaking the first U.S. clinical trial of an iPSC-derived therapeutic. Its Phase I/IIa clinical trial will involve 12 patients with advanced-stage geographic atrophy of the eye.
- Vita Therapeutics, a Cambrian Biopharma affiliate, is developing iPSC-derived therapeutics, including an autologous, genetically engineered iPSC-derived therapeutic (VTA-100) for limb-girdle muscular dystrophy and a genetically engineered iPSC-derived hypoimmunogenic treatment for muscular dystrophy (VTA-200).
iPSC Derived Clinical Trials
The first clinical trial using iPSCs started in 2008, and today, that number has surged worldwide. Most of the current clinical trials do not involve the transplant of iPSCs into humans, but rather, the creation and evaluation of iPSC lines for clinical purposes. Within these trials, iPSC lines are created from specific patient populations to determine if these cell lines could be a good model for a disease of interest.
The therapeutic applications of induced pluripotent stem cells (iPSCs) have also surged in recent years. Since the discovery of iPSCs in 2006, it took only seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2013. Since then, iPSC-derived cells have been used within a rapidly growing number of preclinical studies, physician-led studies, and formal clinical trials worldwide
iPS Cell Market Competitors
In addition to the iPSC cell therapy developers, there are an ever-growing number of competitors who are commercializing iPSC-derived products for use across a diverse range of applications. These applications include drug development and discovery, disease modeling, toxicology testing, and personalized medicine, as well as tissue engineering, 3D bioprinting, and clean meat production.
Across the broader iPSC sector, FUJIFILM CDI is one of the largest and most dominant players. Cellular Dynamics International (CDI) was founded in 2004 by Dr. James Thomson at the University of Wisconsin-Madison, who in 2007 derived iPSC lines from human somatic cells for the first time. The feat was accomplished simultaneously by Dr. Shinya Yamanaka’s lab in Japan. FUJIFILM acquired CDI in April 2015 for $307 million. Today, the combined company is the world’s largest manufacturer of human cells created from iPSCs for use in research, drug discovery and regenerative medicine applications.
Another iPSC specialist is ReproCELL, a company that was established as a venture company originating from the University of Tokyo and Kyoto University in 2009. It became the first company worldwide to make iPSC products commercially available when it launched its ReproCardio product, which are human iPSC-derived cardiomyocytes.
Within the European market, the dominant competitors are Evotec, Ncardia, and Axol Bioscience. Headquartered in Hamburg, Germany, Evotec is a drug discovery alliance and development partnership company. It is developing an iPSC platform with the goal to industrialize iPSC-based drug screening as it relates to throughput, reproducibility, and robustness. Today, Evotec’s infrastructure represents one of the largest and most advanced iPSC platforms globally.
Ncardia was formed through the merger of Axiogenesis and Pluriomics in 2017. Its predecessor, Axiogenesis, was founded in 2011 with an initial focus on mouse embryonic stem cell-derived cells and assays. When Yamanaka’s iPSC technology became available, Axiogenesis became the first European company to license it in 2010. Today, the combined company (Ncardia) is a global authority in cardiac and neural applications of human iPSCs.
Founded in 2012, Axol Bioscience is a smaller but noteworthy competitor that specializes in iPSC-derived products. Headquartered in Cambridge, UK, it specializes in human cell culture, providing iPSC-derived cells and iPSC-specific cell culture products.
Of course, the world’s largest research supply companies are also commercializing a plethora of iPSC-related products. Examples of these market leaders include Lonza, BD Biosciences, Thermo Fisher Scientific, Merck, Takara Bio, STEMCELL Technologies, and others.
iPSC Report Details
This global strategic report reveals all major market competitors worldwide, including their core technologies, strategic partnerships, and products under development. It covers the current status of iPSC research, biomedical applications, manufacturing technologies, patents, and funding events, as well as all known trials for the development of iPSC-derived cell therapeutics worldwide. Importantly, it profiles leading market competitors worldwide and presents a comprehensive market size breakdown for iPSCs by Application, Technology, Cell Type, and Geography (North America, Europe, Asia/Pacific, and Rest of World). It also presents total market size figures with projected growth rates through 2029.
Claim this global strategic report to become immediately informed about the iPSC market, without sacrificing weeks of unnecessary research or missing critical market opportunities.
This global strategic report reveals:
- Market size determinations with segmentation and five-year forecasts
- Clinical trial activity by type, region, phase, and sponsor
- Patent analysis by applicant, type, date and region
- iPSC industry partnerships, alliances, and IPOs
- Emerging trends and future directions
- Competitors composing the global iPSC marketplace
- and much more!
This 327-page global strategic report will position you to:
- Capitalize on emerging trends
- Improve internal decision-making
- Reduce company risk
- Approach outside partners and investors
- Outcompete your competition
- Implement an informed and advantageous business strategy
Table of Contents
1.2 Executive Summary
3.1.1 Examples of Autologous iPSC-Derived Cell Therapies in Development
3.2 Manufacturing Timeline for Autologous iPSC-Derived Cell Products
3.3 Cost of iPSC Production
3.4 Automation in iPSC Production
3.5 Allogeneic iPSCs Gaining Momentum
3.5.1 Ongoing Clinical Trials Involving Allogeneic iPSCs
3.6 Share of iPSC-Based Research Within the Overall Stem Cell Industry
3.7 Major Focus Areas of iPSC Companies
3.8 Commercially Available iPSC-Derived Cell Types
3.9 Relative Use of iPSC-Derived Cell Types in Toxicology Testing Assays
3.10 Currently Available iPSC Technologies
3.10.1 Brief Descriptions of Some Recently Introduced iPSC-Related Technologies
22.214.171.124 Nucleofector Technology
126.96.36.199 Opti-Ox Technology
188.8.131.52 Mogrify Technology
184.108.40.206 Transcription Factor-Based iPSC Differentiation Technology
220.127.116.11 Flowfect Technology
18.104.22.168 Technology for Mass Production of Platelets from Megakaryocytes
22.214.171.124 Synfire Technology
4.2 First Human iPSC Generation, 2007
4.3 Creation of Cira, 2010
4.4 First High-Throughput Screenining Using iPSCs, 2012
4.5 First iPSC Clinical Trial Approved in Japan, 2013
4.6 First iPSC-Rpe Cell Sheet Transplantation for Amd, 2014
4.7 Ebisc Founded, 2014
4.8 First Clinical Trial Using Allogeneic iPSCs for Amd, 2017
4.9 Clinical Trial for Parkinson’S Disease Using Allogeneic iPSCs, 2018
4.10 Commercial iPSC Plant Smart Established, 2018
4.11 First iPSC Therapy Center in Japan, 2019
4.12 First U.S.-Based Nih-Sponsored Clinical Trial Using iPSCs, 2019
4.13 Cynata Therapeutics’ World’S Largest Phase Iii Clinical Trial, 2020
4.14 Tools and Know-How to Manufacture iPSCs in Clinical Trials, 2021
4.15 Production of In-House iPSCs Using Peripheral Blood Cells, 2022
5.1.1 Pubmed Publications on Pathophysiological Research
5.1.2 Pubmed Papers in Reprogramming
5.1.3 Pubmed Papers in iPSC Differentiation
5.1.4 Pubmed Papers on the Use of iPSCs in Drug Discovery
5.1.5 Pubmed Papers on iPSC-Based Cell Therapy
5.2 Percent Share of Published Articles by Disease Type
5.3 Percent Share of Articles by Country
6.2 Patents by Assignee Organization Type
6.3 Ownership of Patent Families by Assignee Type
6.4 Top Inventors of iPSC Patents
6.5 Top Ten iPSC Inventors
6.6 Most Cited Five iPSC Patents
6.7 Leading Patent Filing Jurisdictions
6.8 Number of Patent Families by Year of Filing
6.9 Patents Representing Different Disorders
6.10 iPSC Patents on Preparation Technologies
6.11 Patents on Cell Types Differentiated from iPSCs
6.12 Patent Application Trends Disease-Specific Technologies
7.2 Number of iPSC Clinical Trials by Year
7.3 iPSC Study Designs
7.3.1 Therapeutic and Non-Therapeutic Studies
7.3.2 Non-Therapeutic Clinical Trials by Use
126.96.36.199 Top Ten Countries With the Ongoing Non-Therapeutic Studies
188.8.131.52 Diseases Targeted by Non-Therapeutic Studies
7.3.3 Therapeutic Studies
184.108.40.206 Therapeutic Studies by Phase of Study
220.127.116.11 Therapeutic Studies by Disease Type
18.104.22.168 Examples of Therapeutic Interventional Studies
22.214.171.124 Future Outlook for Therapeutic Clinical Trials Using iPSCs
7.4 iPSC-Based Clinical Trials With Commercialization Potential
8.2 Partial List of Nih Funded iPSC Research Projects in 2022
9.1.1 Evotec & Rigenerand
9.1.2 Catalent & Rheincell Therapeutics
9.1.3 Axol Bioscience & Censo Biotechnologies
9.1.4 Bayer AG & Bluerock
9.1.5 Pluriomics & Axiogenesis
9.2 Partnership/Collaboration/Licensing Deals in iPSC Sector
9.2.1 Evotec & Sernova
9.2.2 Evotec Se & Almirall, Sa
9.2.3 Quell Therapeutics & Cellistic
126.96.36.199 Terms of the Collaboration
9.2.4 Mdimmune & Yipscell
9.2.5 Edigene & Neukio Biotherapeutics
9.2.6 Matricelf & Ramot
9.2.7 Evotec & Boehringer Ingelheim
9.2.8 Plurityx, Pancella & Implant Therapeutics
9.2.9 Century Therapeutics & Bristol Myers Squibb
9.2.10 Terms of the Collaboration
9.2.11 Fujifilm Cellular Dynamics & Pheno Vista Biosciences
9.2.12 Metrion Biosciences & Bioqube Ventures
9.2.13 Cytovia Therapeutics & Cellectis
9.2.14 Exacis Biotherapeutics & Ccrm
9.2.15 Cynata Therapeutics & Fujifilm Corporation
9.2.16 Bone Therapeutics & Implant Therapeutics
9.2.17 Reprocell & Texcell
9.2.18 Jacobio & Herbecell
9.2.19 Neucyte & Kif1A.Org
9.2.20 Kite & Shoreline Biosciences
9.2.21 Neurophth Therapeutics & Hopstem Biotechnology
9.2.22 Allele Biotech & Cellatoz
9.2.23 Bluerock Therapeutics, Fujifilm Cellular Dynamics & Opsis Therapeutics
9.2.24 Newcells & Takeda
9.2.25 Biocentriq & Kytopen
9.2.26 Fujifilm Cellular Dynamics & Sana Biotechnology
9.2.27 Evotec & Medical Center Hamburg-Eppendorf (Uke)
9.2.28 Neucyte & Seaver Autism Center for Research and Treatment
9.2.29 Cytovia Therapeutics & National Cancer Institute
9.2.30 Mogrify & Mrc Laboratory of Molecular Biology
9.3 Venture Capital Funding and Ipos
9.3.1 Aspen Neuroscience
9.3.2 Axol Biosciences Ltd.
9.3.3 Thyas Co. Ltd.
9.3.5 Cellino Biotech, Inc.
9.3.6 Curi Bio
9.3.8 Evotec Se
9.3.10 Clade Therapeutics
9.3.11 Shoreline Biosciences
9.3.13 Cytovia Therapeutics & Cytolynx
9.3.14 Treefrog Therapeutics
9.3.15 Hebecell Corporation
9.3.16 Neukio Biotherapeutics
9.3.17 Stemson Therapeutics
9.3.18 Vita Therapeutics
9.3.19 Century Therapeutics
9.3.22 Metrion Biosciences
9.3.23 Axol Biosciences
9.3.24 Axol Bioscience
9.3.25 Elevate Bio
9.3.26 Vita Therapeutics
10.1.1 Pluripotency-Associated Transcription Factors and Their Functions
10.1.2 Different Combinations of Factors for Different Cell Sources
10.1.3 Delivery of Reprogramming Factors
10.2 Integrating iPSC Delivery Methods
10.2.1 Retroviral Vectors
10.2.2 Lentiviral Vectors
10.2.3 Piggybac (Pb) Transposon
10.3 Non-Integrative Delivery Systems
10.3.1 Adenoviral Vectors
10.3.2 Sendai Viral Vectors
10.3.3 Plasmid Vectors
10.3.5 Orip/Epstein-Barr Nuclear Antigen-1 (Ebna1) Based Episomes
10.4 Comparison of Delivery Methods for Generating iPSCs
10.5 Genome Editing Technologies in iPSC Generation
11.2 Reprogramming Methods Used in iPSC Banking
11.3 Factors Used in Reprogramming in Different Banks
11.4 Workflow in iPSC Banks
11.5 Existing iPSC Banks
11.5.1 California Institute for Regenerative Medicine (Cirm)
188.8.131.52 Cirm iPSC Repository
184.108.40.206 Key Partnerships Supporting Cirm’S iPSC Repository
11.6 Regenerative Medicine Program (Rmp)
11.6.1 Research Grade iPSC Lines for Orphan & Rare Diseases With Rmp
11.6.2 Rmp’S Stem Cell Translation Laboratory (Sctl)
11.7 Center for Ips Cell Research and Application (Cira)
11.8 Fit - Facility for Ips Cell Therapy
11.9 European Bank for Induced Pluripotent Stem Cells (Ebisc)
11.10 Korean Society for Cell Biology (Kscb)
11.11 Human Induced Pluripotent Stem Cell Initiative (Hipsci)
11.12 Riken - Bioresource Research Center (Brc)
11.13 Taiwan Human Disease iPSC Consortium
12.1.1 to Understand Cell Fate Control
12.1.2 to Understand Cell Rejuvenation
12.1.3 to Understand Pluripotency
12.1.4 to Study Tissue & Organ Development
12.1.5 to Produce Human Gametes from iPSCs
12.1.6 Providers of iPSC-Related Services for Researchers
12.2 iPSCs in Drug Discovery
12.2.2 Drug Discovery for Cardiovascular Diseases Using iPSCs
12.2.3 Drug Discovery for Neurological Diseases Using iPSCs
12.2.4 Drug Discovery for Rare Diseases Using iPSCs
12.3 iPSCs in Toxicology Studies
12.3.1 Testing Drugs for Dili
12.3.2 Examples of Drugs Tested in iPSC-Derived Cells
12.3.3 Relative Use of iPSC-Derived Cell Types in Toxicity Testing Studies
12.4 iPSCs in Disease Modeling
12.4.1 Cardiovascular Diseases Modeled With iPSC-Derived Cells
220.127.116.11 Percent Share Utilization of iPSCs for Cardiovascular Disease Modeling
12.4.2 Modeling Liver Diseases Using iPSC-Derived Hepatocytes
12.4.3 iPSCs in Neurodegenerative Disease Modeling
12.4.4 iPSC-Derived Organoids for Modeling and Diseases
12.4.5 Cancer-Derived iPSCs
12.5 iPSCs in Cell-Based Therapies
12.5.1 Companies Focusing Only on iPSC-Based Cell Therapy
12.6 Other Novel Applications of iPSCs
12.6.1 iPSCs in Tissue Engineering
18.104.22.168 3D Bioprinting Techniques
22.214.171.124 3D Bioprinting Strategies
126.96.36.199 Bioprinting iPSC-Derived Cells
12.6.2 iPSCs from Farm Animals
188.8.131.52 Porcine iPSCs
184.108.40.206 Bovine iPSCs
220.127.116.11 Ovine and Caprine iPSCs
18.104.22.168 Equine iPSCs
22.214.171.124 Avian iPSCs
12.7 iPSCs in Animal Conservation
12.7.1 iPSC Lines for the Preservation of Endangered Species of Animals
12.7.2 iPSCs in Wildlife Conservation
12.7.3 iPSCs in Cultured Meat
13.2 Global Market for iPSCs by Technology
13.3 Global Market for iPSCs by Biomedical Application
13.4 Global Market for iPSCs by Derived Cell Type
13.5 Market Drivers
13.5.1 Current Drivers Impacting the iPSC Marketplace
13.6 Market Restraints
13.6.1 Economic Issues
13.6.2 Genomic Instability
14.2 Addgene, Inc.
14.2.1 Viral Plasmids
14.3 Allele Biotechnology, Inc.
14.3.1 iPSC Reprogramming and Differentiation
14.3.2 Cgmp Facility
14.4 Alstem, Inc.
14.4.2 iPSC-Related Products
14.4.3 Human Ips Cell Lines
14.4.4 Inducible Ips Cell Lines
14.4.5 Isogenic Ips Cell Lines
14.4.6 Knockout Cell Lines
14.5 Altos Labs
14.6 Ams Biotechnology Ltd. (Amsbio)
14.6.1 iPSC-Derived Cells and Differentiation Kits
14.6.2 iPSC-Derived Excitatory Neurons
14.6.3 iPSC-Derived Dopaminergic Neurons
14.6.4 iPSC-Derived Gabaergic Neurons
14.6.5 iPSC-Derived Cholinergic Neurons
14.6.6 iPSC-Derived Skeletal Muscle
14.7 Aspen Neuroscience, Inc.
14.7.1 Aspen’S Clinical Pipeline
14.8 Astellas Pharma, Inc.
14.8.1 Leading Program
14.9 Avery Therapeutics
14.10 Axol Bioscience Ltd.
14.10.1 iPSC-Derived Cells
14.10.2 Disease Models
14.10.4 Custom Cell Services
14.10.5 Stem Cell Reprogramming
14.10.6 Genome Editing
14.10.7 Stem Cell Differentiation
14.11.1 Opti-Ox Reprogramming Technology
14.11.3 Iowild Type Cells
14.11.4 Ioglutamatergic Neurons
14.11.5 Ioskeletal Myocytes
14.11.6 Iogabaergic Neurons
14.11.7 Iodisease Models
14.11.8 Ioglutamatergic Neurons Htt50Cagwt
14.12 Bluerock Therapeutics
14.12.1 Cell + Gene Platform
126.96.36.199 Spinal Motor Neurons
188.8.131.52 Midbrain Dopaminergic Neurons
184.108.40.206 Cortical Glutamatergic Neurons
220.127.116.11 Mixed Cortical Neurons
18.104.22.168 Cortical Astrocytes
22.214.171.124 Layer V Glutamatergic Neurons
126.96.36.199 Cortical Gabaergic Neurons
188.8.131.52 Medium Spiny Neurons
184.108.40.206 Spinal Astrocytes
14.14 Brooklyn Immuno Therapeutics
14.14.1 Synthetic Mrna
14.14.2 Non-Viral Nucleic Acid Delivery
14.14.3 Cellular Reprogramming
14.14.4 Gene Editing
14.15 Catalent Biologics
14.15.1 Human iPSCs
14.16 Celogics, Inc.
14.17.1 Lung Cancer Cell Models
14.17.2 Breast Cancer Cell Models
14.17.3 Colon Cancer Cell Lines
14.17.4 Ovarian Cancer Cell Lines
14.17.5 Pancreatic Cancer Cell Lines
14.17.6 Cancer Research Custom Services
14.17.7 Stem Cell Services
14.18 Cellgenix, GmbH
14.19 Cellino Biotech
14.19.1 Cellino’S Technology Platform
14.20 Cellular Engineering Technologies (Cet)
14.20.2 Ips Cell Lines
14.20.3 Drug Discovery Services
14.20.4 iPSC Reprogramming Services
14.21 Censo Biotechnologies, Ltd.
14.22 Century Therapeutics, Inc.
14.22.1 Cell Therapy Platform
14.22.2 Century’S Pipeline
14.23 Citius Pharmaceuticals, Inc.
14.23.1 Stem Cell Platform of Imscs
14.24 Clade Therapeutics
14.25 Creative Bioarray
14.25.1 iPSC Reprogramming Kits
14.25.2 Qualistem Episomal iPSC Reprogramming Kit
14.25.3 Qualistem Rna iPSC Reprogramming Kit
14.25.4 Qualistem Retrovirus iPSC Reprogramming Kit
14.25.5 Qualistem Lentivirus iPSC Reprogramming Kit
14.25.6 Qualistem iPSC Protein Reprogramming Kit
14.25.7 iPSC Characterization Kits
14.25.8 Alkaline Phosphatase Staining Assay
14.25.9 Pluripotency Markers (Protein)
14.25.10 Pluripotency Markers (Mrna)
14.25.11 iPSC Differentiation Kits
14.25.12 Qualistem Ips Cell Cardiomyocyte Differentiation Kit
14.25.13 Qualistem Human Ips Cell Dopaminergic Neuron Differentiation Kit
14.25.14 Qualistem Ips Cell Neural Progenitor Differentiation Kit
14.25.15 Qualistem Ips Cell Endoderm Differentiation Kit
14.25.16 Qualistem Ips Cell Ectoderm Differentiation Kit
14.25.17 Qualistem Ips Cell Mesoderm Differentiation Kit
14.25.18 Qualistem Ips Cell Hepatocyte Differentiation Kit
14.25.19 iPSC Myogenic Progenitor Differentiation Kit
14.26 Curi Bio
14.26.1 Disease Model Development
14.26.2 Assay Development
14.26.4 Cell Repositories
14.27 Cynata Therapeutics Ltd.
14.27.1 Cymerus Platform
14.27.2 Clinical Development
220.127.116.11 Graft Vs. Host Disease
18.104.22.168 Critical Limb Ischemia
22.214.171.124 Acute Respiratory Syndrome
126.96.36.199 Diabetic Wounds
188.8.131.52 Preclinical Development
184.108.40.206 Idiopathic Pulmonary Fibrosis
220.127.116.11 Renal Transplantation
18.104.22.168 Heart Attack
22.214.171.124 Coronary Artery Disease
14.28 Cytovia Therapeutics
14.28.2 Ink & Car-Ink Cells
14.28.3 Flex-Nk Cell Engagers
14.29.1 Optidiff iPSC Platform
126.96.36.199 Phenotypic Screening Services
188.8.131.52 iPSC Differentiation Services
184.108.40.206 Disease Modeling Services
220.127.116.11 Hepatocyte Wt
18.104.22.168 Nafld iPSC-Derived Hepatocytes
22.214.171.124 Gsd1A Disease Modeled Hepatocytes
126.96.36.199 A1Atd Disease Modeled Hepatocytes
188.8.131.52 Hepatocyte Familial Hypercholesterolemia (Fh)
184.108.40.206 Custom Model Development
220.127.116.11 Nafld Pnpla3
18.104.22.168 Nafld Tm6Sf2 Disease Modeled Hepatocytes
22.214.171.124 Intestinal Organoids
126.96.36.199 Intestinal Monolayer
188.8.131.52 Pancreatic Beta Cells (Wt)
184.108.40.206 Mody3 Diabetes
220.127.116.11 Neonatal Diabetes Pancreatic Cells
14.30 Editas Medicine
14.30.1 iPSC-Derived Nk Cells
14.32 Elixirgen Scientific, Inc.
14.32.3 iPSC Products
14.33 Evia Bio
14.33.1 iPSCs Cryopreservation Solutions
14.34 Evotec A.G.
14.34.1 iPSCs Platform
14.34.2 Drug Discoveries
14.35 Exacis Biotherapeutics
14.37 Fate Therapeutics
14.37.1 iPSCs Platform
18.104.22.168 Janssen Biotech
22.214.171.124 Ono Pharmaceutical
14.38 Fujifilm Cellular Dynamics, Inc. (Fcdi)
14.38.2 Mycell Custom Services
14.38.3 Disease Modeling Applications
14.38.4 Drug Discovery Applications
14.38.5 Applications in Toxicity Testing
14.39 Heartseed, Inc.
14.41 Helios K.K.
14.42 Hera Biolabs
14.42.3 Piggybac Transposase/Transposon
14.43 Hopstem Biotechnology
14.43.1 Research & Development
14.43.2 Product Pipeline
14.44 Implant Therapeutics, Inc.
14.45 Ips Portal, Inc
126.96.36.199 Research Support and Contract Testing Services
188.8.131.52 Development Support Services
14.45.2 Business Support
14.46 I Peace, Inc.
14.46.1 Mass Production of iPSCs
14.47 Ixcells Biotechnologies
14.47.3 Ips Cell Generation
14.47.4 Genome Editing
14.47.5 iPSC Differentiation
14.48.1 Flowfect Technology
14.49 Lizarbio Therapeutics
14.50 Lonza Group, Ltd.
14.50.1 iPSC Manufacturing Expertise
14.50.2 Nucleofector Technology
14.52 Merck/Sigma Aldrich
14.52.2 Merck’S iPSC Products and Services
14.53 Megakaryon Corporation
14.53.2 Research and Development Pipeline
14.53.3 Cryopreservable Megakaryon Strain
14.53.4 Treatable Diseases by Products from Megakaryon
14.54 Metrion Biosciences, Ltd.
14.54.1 Cardiac Safety Screening Services
14.54.2 Neuroscience Assay Services
14.54.3 Cardiac Assay Services
14.54.4 Neuroscience Translational Assay Services
14.54.5 Integrated Drug Discovery Service
14.55.1 Mogrify Platform
14.55.2 Epimogrify Platform
14.56.1 iPSC Platform
14.56.2 Human iPSC-Derived Cell Models
14.56.3 Drug Discovery Solutions
14.56.4 Developing iPSC-Derived Cell Types
14.56.5 Assay Development
14.56.6 High-Throughput Screening
14.57.1 Synfire Technology
14.58 Neukio Biotherapeutics
14.59 Newcells Biotech, Ltd
14.59.1 Retinal Platform
14.59.2 Kidney Platform
14.59.3 Lung Model
14.60 Nexel Co. Ltd.
14.60.4 Nexst Cardiac Safety Service
14.61 Orizuru Therapeutics, Inc.
14.61.1 Icm Project
14.61.2 Ipic Project
14.62 Phenocell Sas
14.62.1 Cells and Kits
14.62.2 R&D Outsourcing Services
14.63 Platelet Biogenesis
14.64.1 Rtd and Rtu Technologies
14.65.1 Technology Platform
14.66 Reprocell Usa, Inc.
14.66.1 Rna Reprogramming Kit
14.66.2 Nutristem Culture Medium for Human iPSCs and Es Cells
14.66.3 Induced Pluripotent Stem Cells
14.66.4 Stemrna Neuro
14.66.5 iPSCs Master Cell Bank
14.67 Rxcell, Inc.
14.68 Scg Cell Therapy Pte Ltd.
14.68.1 Acquisition of Technology
14.69 Shoreline Biosciences
14.69.1 Ink Cell Platform
14.69.2 iPSC-Derived Imacs
14.70 Stemson Therapeutics
14.70.1 Hair Follicle Biology
14.71 Stemina Biomarker Discovery
14.71.1 Cardio Quickpredict
14.71.2 Devtox Quickpredict
14.72 Synthego Corp.
14.72.1 Knockout iPSCs
14.72.2 Knock-In iPSCs
14.73 Tempo Bioscience
14.73.1 Human iPSC-Derived Sensory Neurons
14.73.2 Human Ips-Derived Schwann Cells
14.73.3 Human Ips-Derived Phagocytes
14.73.4 Human iPSC-Derived Cd14+ Monocytes
14.73.5 Human iPSC-Derived Cardiomyocytes
14.73.6 Hipsc-Derived Kidney Proximal Tubules and Podocyte 3D Spheroids
14.73.7 Human iPSC-Derived Osteoblasts
14.73.8 Human iPSC-Derived Mscs
14.73.9 Human iPSC-Derived Retinal Pigment Epithelials
14.73.10 Human Ips-Derived Motor Neurons
14.73.11 Human iPSC-Derived Microglia
14.73.12 Human iPSC-Derived Keratinocytes
14.73.13 Human iPSC-Derived Melanocytes
14.73.14 Human iPSC-Derived Dopaminergic Neurons
14.73.15 Human iPSC-Derived Cortical Neurons
14.73.16 Human iPSC-Derived Oligodendrocyte Progenitor Cells (Opcs)
14.73.17 Human iPSC-Derived Astrocytes
14.73.18 Human iPSC-Derived Neural Progenitor Cells
14.74 Thyas, Co. Ltd.
14.74.1 Itcr-T (iPSC-Derived Tcr-T)
14.74.2 Icar-Nk/Ilc (iPSC-Derived Car-Nk/Ilc)
14.74.3 Thya’S Product Pipeline
14.75 Universal Cells
14.75.2 Editing the Genome Without Breaking It
14.75.3 Cells for Every Organ
14.76 Viacyte, Inc.
14.76.1 Pec-01 Cells
14.76.2 Device Engineering
14.77 Vita Therapeutics
14.78 Xcell Science, Inc.
14.78.1 Cell Products
14.78.2 Control Lines
14.79 Yashraj Biotechnology, Ltd.
14.79.1 iPSC and Differentiated Derivatives
184.108.40.206 iPSC-Derived Human Cardiomyocytes
220.127.116.11 iPSC-Derived Hepatocytes
18.104.22.168 iPSC-Derived Astrocytes
22.214.171.124 iPSC-Derived Forebrain Motor Neurons
126.96.36.199 iPSC-Derived Endothelial Cells
188.8.131.52 iPSC-Derived Midbrain Dopaminergic Neurons
14.80.1 R&D Programs
- Addgene, Inc.
- Aleph Farms
- Allele Biotechnology & Pharmaceuticals, Inc.
- Almirall, SA
- ALSTEM, Inc.
- Altos Labs
- American Type Culture Collection (ATCC)
- AMS Biotechnology Ltd. (AMSBIO)
- Applied Biological Materials, Inc. (ABM)
- Applied StemCell (ASC), Inc.
- Aruna Bio, Inc.
- Aspen Neuroscience, Inc.
- Astellas Pharma, Inc.
- Avery Therapeutics
- Axol Bioscience, Ltd.
- Bayer AG
- BD Biosciences
- Beckman Coulter Life Sciences
- BioCat GmbH
- Bioqube Ventures
- BlueRock Therapeutics (acquired by Bayer)
- Boehringer Ingelheim
- Bone Therapeutics
- Bristol Myers Squibb (BMS)
- Brooklyn Immuno Therapeutics
- Catalent Biologics
- Cell Biolabs, Inc.
- Cell Signaling Technology
- CellGenix GmbH
- Cellino Biotech, Inc.
- Cellular Dynamics International, Inc.
- Cellular Engineering Technologies (CET)
- Celogics, Inc.
- Censo Biotechnologies, Ltd.
- Century Therapeutics
- Citius Pharmaceuticals, Inc.
- Clade Therapeutics
- Corning, Inc.
- Creative Bioarray
- Curi Bio
- Cynata Therapeutics Ltd.
- Cytovia Therapeutics
- Editas Medicine
- Elixirgen Scientific, Inc.
- Evia Bio
- Exacis Biotherapeutics
- Fate Therapeutics, Inc.
- Fujifilm Cellular Dynamics, Inc. (FCDI)
- Fujifilm Corporation
- GeneCopoeia, Inc.
- GenTarget, Inc.
- Healios K.K.
- Heartseed, Inc.
- HebeCell Corporation
- Helios K.K.
- Hera Biolabs
- Hopstem Biotechnology
- I Peace, Inc.
- Implant Therapeutics, Inc.
- iPS Portal, Inc.
- iXCells Biotechnologies
- Keio University
- Kyoto University Hospital
- Lizarbio Therapeutics
- Lonza Group, Ltd.
- Medical Center Hamburg-Eppendorf (UKE)
- Megakaryon Corporation
- Memorial Sloan-Kettering Cancer Center
- Merck/Sigma Aldrich
- Metrion Biosciences, Ltd.
- Miltenyi Biotec B.V. & Co. KG
- MRC Laboratory of Molecular Biology
- National Cancer Institute
- Neukio Biotherapeutics
- Neurophth Biotechnology Ltd.
- Newcells Biotech, Ltd.
- Nexel Co. Ltd.
- Novo Nordisk
- ONO Pharmaceutical Co., Ltd.
- Opsis Therapeutics
- Orizuru Therapeutics, Inc.
- Osaka University
- Oslo University Hospital
- Pheno Vista Biosciences
- Phenocell SAS
- Platelet Biogenesis
- Pluricell Biotech
- PromoCell GmbH
- Quell Therapeutics
- R&D Systems, Inc.
- ReproCELL USA, Inc.
- Rheincell Therapeutics
- RxCell, Inc.
- Sana Biotechnology
- SCG Cell Therapy Pte. Ltd.
- SCM Lifescience
- Seaver Autism Center for Research & Treatment
- Semma Therapeutics
- Shoreline Biosciences
- STEMCELL Technologies
- Stemina Biomarker Discovery
- Stemson Therapeutics
- Sumitomo Dainippon Pharma
- Synthego Corp.
- System Biosciences (SBI)
- Takara Bio
- Takeda Pharmaceutical Co., Ltd.
- Tempo Bioscience
- Thermo Fisher Scientific, Inc.
- Thyas Co. Ltd.
- Treefrog Therapeutics
- U.S. NIH
- Universal Cells
- University of California
- Vertex Pharmaceuticals
- Viacyte, Inc.
- VistaGen Therapeutics, Inc.
- Vita Therapeutics
- Waisman Biomanufacturing
- xCell Science, Inc.
- Yashraj Biotechnology, Ltd.
The content and statistics contained within the publisher's reports are compiled using a broad range of sources, as described below.
- Clinical Trial Databases (ClinicalTrials.gov, International Clinical Trials Registry Platform, European Union Clinical Trials Register, Chinese Clinical Trial Registry, Others)
- Scientific Publication Databases (PubMed, Highwire Press, Google Scholar)
- Patent Databases (United States Patent and Trade Office, World Intellectual Property Organization, Google Patent Search)
- Grant Funding Databases (RePORT Database, CIRM, MRC, Wellcome Trust - UK, Others)
- Product Launch Announcements (Trade Journals, Google News)
- Industry Events (Google News, Google Alerts, Press Releases)
- Company News (SEC Filings, Investor Publications, Historical Performance)
- Social Analytics (Google Adwords, Google Trends, Twitter, Topsy.com, Hashtagify.me, BuzzSumo.com)
- Interviews with Stem Cell Industry Leaders
Research & Analysis Methodologies
The publisher employs the following techniques for deriving its market research:
- Historical Databases: As the first and only market research firm to specialize in the stem cell industry, the publisher has 13+ years of historical data on each segment of the stem cell the industry. This provides an extremely rare and robust database for establishing market size determinations, as well as making future market predictions.
- Prolific Interviews with Industry Leaders: As the global leader in stem cell industry data, the publisher has interviewed hundreds of leaders from across the stem cell industry, including the CEO of FUJIFILM CDI, FUJIFILM Irvine Scientific, Pluristem Therapies, Celularity, and many others.
- Industry Relationships: The research team and its President/Founder, Cade Hildreth, Chair and present at a wide range of stem cell industry events, including Phacilitate's Advanced Therapies Week, World Stem Cell Summit (WSCS), Perinatal Stem Cell Society Congress, AABB's International Cord Blood Symposium (ICBS), and other events hosted within the U.S. and worldwide.
- Global Integrated Feedback: Because the publisher maintains the world's largest stem cell industry news site that is read by nearly a million unique readers per year and the company has large social media audiences (25.7K+ followers on Linked, 21.2K+ followers on Twitter, and 4.3K+ followers on Facebook), the publisher is able to publish content relevant to the industry and receive immediate feedback/input from a global community of readers. In short, the publisher's data is crowd-sourced from market participants worldwide, including those in diverse geographic regions.
- Preliminary Research: In addition to the interviews described above, the publisher conducts market surveys, executes social media polls, and aggregates market data from stem cell industry announcements, press releases, and corporate filings/presentations.
- Secondary Research: The publisher summarizes, collects and synthesizes existing market research that is relevant to the market area of interest.
- Future Projections: Using the resources described above, the publisher is uniquely positioned to make future projections about market size, market growth by segment, market trends, technology evolution, funding activities (financing rounds, M&A, and IPOs), and importantly, market leadership (market share by company).